The U.S. Food and Drug Administration (FDA) has announced a new initiative aimed at accelerating the repurposing of already approved medicines to treat diseases with significant unmet medical needs, including rare disorders, neurodegenerative diseases, metabolic conditions, and substance use disorders.
Under the initiative, the FDA is seeking public input from researchers, clinicians, patients, pharmaceutical companies, and healthcare organizations on potential new uses for existing drugs. The agency said the move could help bring treatments to patients faster by leveraging already available safety and effectiveness data for approved medicines.
According to the FDA, the effort will particularly focus on medicines where there is little or no commercial interest in pursuing new supplemental approvals despite promising scientific evidence. The regulator has opened a public docket to collect information on disease priorities, candidate drugs, innovative research approaches, and barriers preventing repurposing efforts.
The initiative is expected to benefit areas where drug development remains slow or financially challenging, especially rare diseases and chronic conditions that currently lack effective treatment options. Experts believe drug repurposing can significantly reduce development timelines and costs compared to developing entirely new molecules.
Industry observers noted that the FDA may increasingly rely on real-world evidence, published scientific literature, and existing clinical data to support label expansions for approved drugs. Recent examples cited by analysts include the FDA’s use of existing data to expand therapeutic applications for older medicines in specialized conditions.
The FDA said priority therapeutic areas under consideration include women’s and men’s health conditions, neurodegenerative disorders, metabolic diseases, rare diseases, and substance use disorders. The agency also indicated it may collaborate with organizations such as the National Institutes of Health and the Centers for Medicare & Medicaid Services to support the initiative.
Drug repurposing has gained increasing attention globally as pharmaceutical companies and regulators look for faster and more cost-effective ways to expand patient access to therapies. The strategy involves identifying new therapeutic uses for medicines that are already approved or previously studied, potentially shortening the path to clinical use because much of the safety profile is already established.
The FDA has invited stakeholders to submit comments and scientific information under docket number FDA-2026-N-4492 as part of the ongoing consultation process.
